Breast Neoplasms
📧 Sign up to get email alerts when something new happens for Breast Neoplasms.
Sign up freeTop drugs studied for this disease
-
EMA withdrawal · 2022-12-13EMA Application withdrawn: Tuznue (trastuzumab) — Prestige Biopharma Belgium
The EMA has withdrawn the application for Tuznue (trastuzumab) by Prestige Biopharma Belgium.
-
EMA withdrawal · 2022-12-13EMA Application withdrawn: Hervelous (trastuzumab) — Prestige Biopharma Belgium
The EMA indicates an application for Hervelous (trastuzumab) by Prestige Biopharma Belgium has been withdrawn.
-
EMA withdrawal · 2022-05-20EMA Withdrawn: Docetaxel Zentiva (previously Docetaxel Winthrop) (docetaxel) — Zentiva k.s.
The EMA has withdrawn Docetaxel Zentiva (docetaxel) from the market. The therapeutic areas formerly associated include head and neck neoplas…
-
EMA withdrawal · 2021-12-14EMA Withdrawn: Docetaxel Teva (docetaxel) — Teva B.V.
The EMA has withdrawn Docetaxel Teva, an injectable chemotherapy containing docetaxel, from the European market.
-
EMA withdrawal · 2021-11-25EMA Withdrawn: Equidacent (bevacizumab) — Centus Biotherapeutics Europe Limited
Equidacent (bevacizumab) has been withdrawn from the market in the European Medicines Agency record.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA withdrawal · 2020-07-27EMA Application withdrawn: Doxorubicin Hydrochloride Tillomed (doxorubicin hydrochloride) — Laboratorios Tillomed Spain S.L.U
The EMA withdrew the application for doxorubicin hydrochloride from Laboratorios Tillomed Spain S.L.U. for several cancer indications includ…
-
EMA withdrawal · 2019-10-15EMA Withdrawn: Taxespira (previously Docetaxel Hospira UK Limited ) (docetaxel trihydrate) — Hospira UK Limited
The EMA withdrew Taxespira (docetaxel trihydrate) from the market for multiple cancer indications including stomach, prostate, breast, head …
-
EMA withdrawal · 2018-02-02EMA Refused: Onzeald (etirinotecan pegol) — Nektar Therapeutics UK Limited
EMA refused approval of Onzeald (etirinotecan pegol) by Nektar Therapeutics UK Limited for breast neoplasms.
-
EMA withdrawal · 2017-11-10EMA Application withdrawn: Kyomarc (bevacizumab) — Amgen Europe B.V.
The EMA withdrew the application for Kyomarc (bevacizumab) from Amgen Europe B.V., relating to several carcinomas and neoplasms.
-
EMA withdrawal · 2016-12-22EMA Withdrawn: Capecitabine SUN (capecitabine) — Sun Pharmaceutical Industries Europe B.V.
Capecitabine SUN (capecitabine) has been withdrawn from the European market by Sun Pharmaceutical Industries Europe B.V.
-
EMA withdrawal · 2016-09-29EMA Application withdrawn: Docetaxel SUN — Sun Pharmaceutical Industries Europe B.V.
The EMA withdrew the application for Docetaxel SUN by Sun Pharmaceutical Industries Europe B.V. for multiple cancer indications.
-
EMA withdrawal · 2015-03-12EMA Lapsed: Docetaxel Mylan (docetaxel) — Mylan S.A.S.
EMA status shows Docetaxel Mylan has lapsed; related indications include head and neck neoplasms, non-small cell lung carcinoma, adenocarcin…
-
CLINICAL_TRIALS withdrawal · 2014-08-25Clinical Trial Update: MBI and Breast Tomosynthesis Screening Accuracies in Patients With Dense Breast Tissue [NA]
A clinical trial evaluating molecular breast imaging (MBI) and breast tomosynthesis for screening in women with dense breast tissue has been…
-
EMA withdrawal · 2012-06-14EMA Withdrawn: Docefrez (docetaxel) — Sun Pharmaceutical Industries Europe B.V.
Withdrawn EMA entry for Docefrez (docetaxel) by Sun Pharmaceutical Industries Europe B.V.; listed indications include stomach neoplasms, ade…
-
EMA withdrawal · 2011-08-22EMA Application withdrawn: Ibandronic Acid Hexal (ibandronic acid) — Hexal AG
The EMA withdrew the application for Ibandronic Acid Hexal (ibandronic acid) from the market. Therapeutic areas listed include hypercalcemia…
-
EMA withdrawal · 2010-03-26EMA Application withdrawn: Docetaxel Mylan (docetaxel) — Mylan S.A.S.
Withdrawal of the EMA application for Docetaxel Mylan (docetaxel) by Mylan S.A.S., affecting multiple solid tumor indications including non-…
-
EMA withdrawal · 2010-03-22EMA Withdrawn: Paxene (paclitaxel) — Norton Healthcare Ltd.
Paxene (paclitaxel) is withdrawn from consideration by Norton Healthcare Ltd., affecting indications including sarcoma (Kaposi), non-small c…
-
EMA withdrawal · 2009-03-19EMA Application withdrawn: Ixempra — Bristol-Myers Squibb Pharma EEIG
The EMA withdrew the marketing authorization application for Ixempra (paclitaxel) from Bristol-Myers Squibb Pharma EEIG in the breast cancer…